Abstract
19520 Background: To evaluate the efficacy and safety of low dose Thalidomide and Dexamethasone in previously untreated patients with Multiple Myeloma. Methods: 34 patients (M/F: 21/13), of median age 57.8 years (range 37–74) with previously untreated symptomatic Myeloma were recruited between October 2005 and June 2007 and were treated with Thalidomide 100mg daily and Dexamethasone (40mg daily x 4days) once monthly for 6 months. All patients were investigated with serum protein electrophoresis, skeletal survey and bone marrow aspiration & biopsy. In addition, b2-microglobulin (18/34) and immunoglobulin electrophoresis (24/34) were done in a subset. Patients had IgG (12), IgA (8), IgM (1) & light chain (3) Myeloma. Response was determined as per the EBMT criteria (CR defined as Plasma cells <_5% in bone marrow) after 6 months of therapy. Results: 33 patients are evaluable for toxicity as 1 was lost for follow up after she developed a second malignancy (CA Breast). 28 patients are evaluable for response, a...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call